Mokari Atabak's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Sep 3, 2026
- Accession no.
- 0001193125-26-382463
- Filed
- Sep 3, 2026, 9:06 PM ET
- Trade date
- Sep 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mokari AtabakCIK 0001678419 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Common Stock | AGrant or awardAcquired | +138 | $113.38F2 | +$15,646.44 | 16,268 | Direct | |
| Sep 1, 2026 | Common Stock | AGrant or awardAcquired | +138 | $0.00 | $0 | 16,406 | Direct | |
| Sep 2, 2026 | Common Stock | FTax withholdingDisposed | −102 | $113.38F6 | −$11,564.76 | 16,304 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F6
The closing price on September 1, 2026 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.